Clinical trial
Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or…
NCT00112931 · University College, London, Other · Completed
Key facts
| NCT number | NCT00112931 |
|---|---|
| Title | Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma |
| Official title | An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy in Patients With Advanced Stage, Asymptomatic, Non-Bulky Follicular Lymphoma |
| Lead sponsor | University College, London, Other |
| Collaborators | Cancer Research UK Roche Pharma AG Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Other |
| Interventions | rituximab, No treatment |
| Enrollment | 462 |
| Start date | Sep 1, 2004 |
| Primary completion | Mar 1, 2014 |
| Completion | Sep 14, 2023 |
| First posted | Jun 3, 2005 |
| Last update posted | May 9, 2024 |
| Countries | Australia, New Zealand, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: